ABSTRACT
INTRODUCTION
Population-based studies report a poor prognosis for patients with newly diagnosed glioblastoma multiforme (GBM), with 1-year, 2-year, and 5-year survival rates at 17% to 30%, 2% to 8%, and 1% to 3%, respectively. GBM is characterized by sustained angiogenesis; the key regulator of tumor angiogenesis is VEGF, which is frequently overexpressed in GBM 8,9 as well as other tumor types ( Figure   1 ). Bevacizumab inhibits VEGF 10 and has been shown in preclinical models to have activity against GBM both alone and in combination with radiotherapy and temozolomide.
11,12
Bevacizumab has also shown considerable potential to provide clinical benefit for patients with GBM (see below).
BEVACIZUMAB TRIAL DATA IN GBM
Various exploratory noncomparative clinical trials provided initial data suggesting that bevacizumab alone or in combination with irinotecan is active and has a manageable safety profile in patients with recurrent GBM. 13, 14 This benefit and safety profile was confirmed in a randomized, noncomparative phase 2 Figure 1 . 
AVAGLIO TRIAL
A large, randomized, double-blind, placebo- It is planning to recruit a total of approximately 920 patients at approximately 140 centers worldwide. 21, 22 This study aims to determine the benefit to risk profile in newly diagnosed GBM patients.
Study Objectives
The 
Study Design and Therapy
Eligible patients are randomized (1:1) 
CONCLUSION
Given the dismal prognosis of newly diagnosed GBM despite treatment with the current standard of care, any treatment that 
